HC Wainwright set a $4.00 price target on Pluristem Therapeutics (NASDAQ:PSTI) in a research report released on Friday morning. The firm currently has a buy rating on the biotechnology company’s stock.
A number of other analysts have also issued reports on the stock. Maxim Group set a $3.00 price target on shares of Pluristem Therapeutics and gave the stock a buy rating in a research note on Wednesday, February 21st. Zacks Investment Research upgraded shares of Pluristem Therapeutics from a hold rating to a buy rating and set a $1.75 price target for the company in a research note on Thursday, March 15th. MED restated a positive rating on shares of Pluristem Therapeutics in a research note on Monday, April 23rd. Finally, ValuEngine upgraded shares of Pluristem Therapeutics from a strong sell rating to a sell rating in a research note on Wednesday, May 2nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. Pluristem Therapeutics presently has an average rating of Buy and a consensus target price of $3.38.
Shares of PSTI traded up $0.04 during mid-day trading on Friday, reaching $1.42. 269,867 shares of the stock traded hands, compared to its average volume of 365,414. The firm has a market capitalization of $147.45 million, a P/E ratio of -4.44 and a beta of 0.27. Pluristem Therapeutics has a 12-month low of $1.39 and a 12-month high of $1.44.
In related news, Director Mark Germain sold 45,873 shares of Pluristem Therapeutics stock in a transaction on Friday, March 16th. The shares were sold at an average price of $1.48, for a total value of $67,892.04. Following the completion of the sale, the director now owns 525,584 shares in the company, valued at $777,864.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 7.20% of the stock is currently owned by insiders.
An institutional investor recently bought a new position in Pluristem Therapeutics stock. Meitav Dash Investments Ltd. purchased a new stake in shares of Pluristem Therapeutics Inc. (NASDAQ:PSTI) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 100,000 shares of the biotechnology company’s stock, valued at approximately $138,000. Meitav Dash Investments Ltd. owned 0.09% of Pluristem Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 4.14% of the stock is owned by institutional investors.
About Pluristem Therapeutics
Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.